JBCPL to acquire brands from Sanzyme for Rs 628 Cr
Mumbai-based JB Chemicals & Pharmaceuticals Limited (JBCPL) will acquire brands for the Indian market from Sanzyme, a leading player in the probiotics and reproductive health segment in the country.
The transaction is valued at Rs 628 crore and is expected to be completed in the next two weeks subject to customary closing formalities.
Sanzyme, ranked amongst the top five probiotics players in the country, is engaged in the manufacture, distribution and marketing of speciality probiotics formulations, infertility management products and nutraceuticals products. It operates in the gastroenterology, nephrology, urology and gynaecology therapy areas with leading brands such as Sporlac, Lobun, and Gynogen. As per IQVIA MAT Dec 21 data, the revenue for the combined brands was Rs 160 crores.
The acquired brands have a pan-India presence and wide distribution reach of ~ 300,000 chemists and ~100,000 prescribers. Probiotics portfolio includes Sporlac (which is the third largest probiotics brand in India) and specialized products such as Lobun (A probiotic used for delaying progression of Chronic Kidney Disease) and Oxalo (alternate risk-free therapy to decalcify kidney stones). The reproductive health segment has a complete range of infertility and hormone
products. Following the acquisition, these products will derive significant visibility by leveraging JBCPL’s distribution network across the country.